Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Иванов М.В., Шипилин М.Ю., Банщиков Ф.Р. Опыт применения арипипразола (абилифая) в лечении больных шизофренией. Соц. и клин. психиатрия. 2009; 19 (2): 46–50. 2. Иванов М.В., Мазо Г.Э., Чомский А.Н. и др. Сероквель: перспективы и опыт терапии маний при биполярных аффективных расстройствах. Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2004; 1 (4). 3. Мосолов С.Н., Костюкова Е.Г., Цукарзи Э.Э. Федеральные клинические рекомендации по диагностике и лечению биполярного аффективного расстройства у взрослых (проект). 2013; http://psychiatr.ru/news/183 4. Софронов А.Г., Спикина А.А., Парфенов Ю.А., Савельев А.П. Динамика назначаемости антипсихотиков в Санкт-Петербурге (2006–2011). Соц. и клин. психиатрия. 2012; 22 (4): 63–8. 5. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Dis 1998; 50: 143–51. 6. Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS Drugs 2007; 21 (9): 727–40. 7. Berk M, Brnabic A, Dodd S et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Dis 2011; 13 (1): 87–98. 8. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiat 2009; 8: 16. 9. Fountoulakis KN, Vieta E, Sanchez-Moreno J et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Dis 2005; 86: 1–10. 10. Fountoulakis KN. The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. CNS Spectr 2008; 13: 763–74. 11. Gonzalez-Pinto A, Mosquera F, Alonso M et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Dis 2006; 8 (5 Pt. 2): 618–24. 12. Green B. Focus on aripiprazole. Curr Med Res Opin 2004; 20: 207–13. 13. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiat 2009; 10 (2): 85–116. 14. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009; 66 (4): 358–65. 15. http://www.medscape.com/viewarticle/820275 16. Jorge M, Tamayo CA, Zarate Jr et al. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2010; 13 (6): 813–32. 17. Keck PE, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study vs. placebo. J Clin Psychiat 2007; 68: 1480–91. 18. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18: 251–67. 19. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiat Scand 2002; 105: 164–72. 20. Sajatovic M, Valenstein M, Blow F et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiat Serv 2007; 58 (6): 855–63. 21. Sajatovic M, Valenstein M, Blow FC et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Dis 2006; 8 (3): 232–41. 22. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiat 2002; 159 (11): 1927–9. 23. Sylvia LG, Hay A, Ostacher M et al. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol 2013; 33 (3): 343–50. 24. Thompsona A, Sullivana SA, Barleya M et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial. Psychological Med 2008; 38 (5): 705–15. 25. Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. Antipsychotics in bipolar disorders. Encephale 2004; 30 (5): 417–24. 26. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2-receptor partial agonist. Exp Opin Invest Drugs 2007; 16: 771–5. 27. Young AH, Oren DA, Lowy A et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiat 2009; 194: 40–8.